Janssen gets EC approval for Darzalex combination regimen to treat multiple myeloma
This article was originally published here
Daratumumab is a first-in-class biologic designed to target CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage. Daratumumab is considered to
The post Janssen gets EC approval for Darzalex combination regimen to treat multiple myeloma appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!